"The
Report PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and
Market Analysis to 2025 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Psoriatic arthritis (PsA) is a
chronic immune-mediated arthritis typically affecting the large
joints, especially those of the lower extremities and distal joints
of the fingers and toes as well as the back and sacroiliac joints of
the pelvis. In approximately 80% of PsA patients, skin lesions of
psoriasis (PsO), an immune-mediated skin disease, manifest prior to
the development of PsA, typically by five to 10 years. PsA most
commonly develops between the ages of 30 and 50 and affects men and
women equally. Although, early diagnosis and intervention are key in
preventing irreversible joint damage, many PsA patients are
undiagnosed and go untreated for months or years.
GlobalData projects the PsA
market in 7MM to experience strong growth during the forecast period
at a CAGR of 10.74%. By the forecast's end in 2025, sales will
increase to over $12.58 billion from $4.53 billion in 2015. This
growth will be driven primarily by the increase in diagnosed
prevalent cases from 1,044,022 in 2015 to 1,520,471 in 2025. Further,
the launch of the IL-17 inhibitors, including Novartis' Cosentyx, Eli
Lilly's Taltz, and AstraZeneca's Lumicef, as well as the launch of
Celgene's oral therapy Otezla, will expand the treatment
armamentarium for PsA driving growth in the market.
View Report @
http://www.marketresearchreports.biz/analysis/990986
Highlights
Key Questions Answered
- How large an impact will
biosimilars have on the PsA market? What do dermatologists,
rheumatologists, and key opinion leaders across the 7MM think about
the evolving treatment landscape?
- What opportunities remain in
the market for new product entrants?
- What are the most promising
late-stage pipeline drugs and how will their launch shape the future
treatment landscape in the PsA market?
- According to KOLs, what are
the most important unmet needs in PsA? Will these needs be addressed
by pipeline agents? What needs will remain by the end of the forecast
period in 2025?
- What clinical and commercial
factors are likely to affect uptake of PsA therapies in the US, 5EU,
and Japan?
Key Findings
- The PsA market is currently
very dynamic, with effective biologic therapies recently approved,
including interleukin-17 (IL-17) inhibitors - Cosentyx, Taltz, and
Lumicef - and oral phosphodiesterase-4 (PDE4) - Otezla.
- Novel biologic therapies will
challenge the current anti-TNF biologics in an attempt to dislodge
their stronghold, if their safety and efficacy profiles are proven
once they enter the market.
- The impending patent cliff
for biologics will allow for the emergence of biosimilars to all the
marketed biologic brands. Patent expiries take place during the
forecast period for the current market leaders such as Johnson &
Johnsons Remicade (infliximab), AbbVies Humira (adalimumab), Amgens
Enbrel (etanercept) and Johnson & Johnsons Stelara (ustekinumab).
- The drivers for market growth
will include the increasing diagnosis rate as well as the recent
approval of novel therapies. The main challenge for individual drugs
will be to distinguish themselves in a crowded marketplace,
comprising a highly diversified field of therapies, with existing
drugs struggling to increase their patient share.
Get
Sample Copy Of This Report At :
Scope
- Overview of PsA, including
epidemiology, etiology, pathophysiology, symptoms and
country-specific diagnosis and treatment recommendations.
- Annualized PsA market
revenue, annual cost of therapy and treatment usage pattern data from
2015 and forecast for ten years to 2025.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, and implications for the PsA market.
- Pipeline analysis:
comprehensive data split across different phases, emerging novel
trends under development, synopses of innovative early-stage
projects, and detailed analysis of novel products- including
promising IL-17 inhibitors - and biosimilars - such as Celltrions
Hospira, Sandozs Erelzi, Biogen/Samsung Bioepies Flixabi and
Benepali, and Amgens Amjevita.
- Analysis of the current and
future market competition in the global PsA market (7MM). Insightful
review of the key industry drivers, restraints and challenges. Each
trend is independently researched to provide qualitative analysis of
its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies
by understanding the trends shaping and driving the global Psoriasis
market.
- Drive revenues by
understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the Psoriasis market
in the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the
global PsA market from 2015-2025.
- Organize your sales and
marketing efforts by identifying the market ca
Table
of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 18
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 20
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Etiology and
Pathophysiology 22
3.1.1 Etiology 22
3.1.2 Pathophysiology 24
3.2 Symptoms 26
3.3 Quality of Life 27
4 Epidemiology 28
4.1 Disease Background 28
4.2 Risk Factors and
Comorbidities 30
4.3 Global Trends 31
4.4 Forecast Methodology 32
4.4.1 Sources Used 32
4.4.2 Forecast Assumptions and
Methods 33
4.4.3 Sources Not Used 40
4.5 Epidemiological Forecast
for PsA (2015-2025) 41
4.5.1 Diagnosed Prevalent Cases
of PsA 41
4.5.2 Age-Specific Diagnosed
Prevalent Cases of PsA 43
4.5.3 Sex-Specific Diagnosed
Prevalent Cases of PsA 45
4.5.4 Age-Standardized
Diagnosed Prevalence of PsA 47
4.5.5 Diagnosed Prevalent Cases
by Type 49
4.5.6 Diagnosed Prevalent Cases
by Joint Involvement 50
4.6 Alternative Forecast of
Diagnosed Prevalent Cases of PsA 50
4.7 Discussion 52
4.7.1 Epidemiological Forecast
Insight 52
4.7.2 Limitations of the
Analysis 53
4.7.3 Strengths of the Analysis
54
5 Disease Management 56
5.1 Diagnosis and Treatment
Overview 56
5.1.1 Diagnosis 56
5.1.2 Disease Activity 58
5.1.3 Treatment Guidelines and
Leading Prescribed Drugs 59
5.1.4 Clinical Practice 68
5.2 US 70
5.3 5EU 71
5.4 Japan 74
6 Competitive Assessment 76
6.1 Overview 76
6.2 Product Profiles - Major
Brands 77
6.2.1 Enbrel (etanercept) 77
6.2.2 Humira (adalimumab) 81
6.2.3 Simponi (golimumab) 85
6.2.4 Remicade (infliximab) 89
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
us:
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
USA:
Canada Toll Free: 866-997-4948
No comments:
Post a Comment